3-heteroaryl-3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists
US7687523B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 9, 2007 |
| Grant date | Mar 30, 2010 |
| Priority date | — |
| Expiry date | Feb 9, 2027 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of the class 3,9-diaza-bicyclo [3.3.1]nonane derivatives. The compounds correspond to structural Formula (I):wherein Ra is hydrogen or optionally substituted alkyl and Rb is a monocyclic heteroaryl group. The compounds are useful in the treatment, prevention, or alleviation of diseases or disorders or conditions that are responsive to modulation of nicotinic acetylcholine receptors, including cognitive disorders, Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), Tourette's syndrome, Bipolar Disorder, obsessive compulsive disorders (OCD), narcolepsy, senile dementia, autism, Parkinson'disease, Amyotrophic Lateral Sclerosis, epilepsy, and diabetic neuropathy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.